Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | ADH4 | P08319 | 1/20 | 0.33 |
| ▸ | ADH7 | P40394 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8299370 | 0.93 | TSHR (0.37) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL28100015 | 0.91 | ADH1B (0.39) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL10689088 | 0.91 | ADH1B (0.39) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL10497894 | 0.91 | ADH1B (0.39) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL3337621 | 0.91 | TSHR (0.35) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL27332979 | 0.89 | TSHR (0.34) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL1972051 | 0.89 | TSHR (0.34) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL27883854 | 0.86 | ADH1B (0.44) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL27791022 | 0.86 | ADH1B (0.44) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL16428382 | 0.85 | TSHR (0.42) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | disclosed |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| EP-4011454-A1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION | Shuttle Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20220055988-A1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | SHUTTLE PHARMACEUTICALS INC (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220031665-A1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) NANO-FORMULATION OF COMPOUNDS AND METHODS OF USING THE SAME | SHIFA BIOMEDICAL CORPORATION | 2022-02-03 | — | — | US | disclosed |
| EP-3877359-A1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) NANO-FORMULATION OF COMPOUNDS AND METHODS OF USING THE SAME | Shifa Biomedical Corporation (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-3265073-B1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | SHUTTLE PHARMACEUTICALS INC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| EP-3844193-A1 | BIS-PHENYL-PHENOXY POLYOLEFIN PROCATALYSTS HAVING TWO ANTHRACENYL LIGANDS | Dow Global Technologies LLC (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3791724-A1 | TREATMENT OF BREAST CANCER | Medivation Prostate Therapeutics LLC (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20040092559-A1 | Bicyclic modulators of androgen receptor function | HAMANN LAWRENCE (US) | 2004-05-13 | — | — | US | disclosed |
| EP-1414795-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-29 | — | — | US | disclosed |
| US-6670386-B2 | For therapy of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | disclosed |
| WO-2003096980-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030195207-A1 | 3-Aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-16 | — | — | US | disclosed |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-20 | — | — | US | disclosed |
| WO-2003011824-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-13 | — | — | WO | disclosed |
| EP-1023301-A1 | A HETEROCYCLIC CHEMICAL COMPOUND | PERSTORP AB (SE) | 2000-08-02 | — | — | EP | disclosed |
| WO-1997018220-A1 | A HETEROCYCLIC CHEMICAL COMPOUND | PERSTORP AB (SE) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | TSHR 491/4885ALDH1A1 1211/4885ADH1B 1076/4885 |
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | TSHR 2502/4885ALDH1A1 911/4885ADH1B 825/4885 |
| US-20220031665-A1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) NANO-FORMULATION OF COMPOUNDS AND METHODS OF USING THE SAME | PCSK9, PCSK6, PCSK7 | TSHR 3718/4885ALDH1A1 4504/4885ADH1B 2344/4885 |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | TSHR 365/4885ALDH1A1 763/4885ADH1B 759/4885 |
| US-20030195207-A1 | 3-Aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators | ESR2, GPER1, ESR1 | TSHR 680/4885ALDH1A1 267/4885ADH1B 1009/4885 |
| US-20040092559-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | TSHR 365/4885ALDH1A1 763/4885ADH1B 759/4885 |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | TSHR 2502/4885ALDH1A1 911/4885ADH1B 825/4885 |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | TSHR 2502/4885ALDH1A1 911/4885ADH1B 825/4885 |
| US-20220055988-A1 | DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF | ATM, HDAC8, HDAC1 | TSHR 3646/4885ALDH1A1 3087/4885ADH1B 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.